SOLICITATION NOTICE
B -- Consulting Services on Human Genetics and Infection with Human T Lymphotropic Virus Type I (HTLV-I)
- Notice Date
- 3/16/2005
- Notice Type
- Solicitation Notice
- NAICS
- 541990
— All Other Professional, Scientific, and Technical Services
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Research Contracts Br., 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852
- ZIP Code
- 20852
- Solicitation Number
- Reference-Number-NCI-50034-NV
- Response Due
- 3/31/2005
- Archive Date
- 4/15/2005
- Description
- In accordance with simplified acquisition procedures The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), Viral Epidemiology Branch (VEB) proposes to acquire, on a sole source basis, the consulting services of Dr. Shunro Sonoda, Kagoshima University, 8 35 1 Sakuragaoka, Kagoshima, Japan for a five month base year with one seven month option period. HTLV-I, the prototype human retrovirus, is known to cause adult T-cell leukemia/lymphoma (ATL), HTLV-associated myelopathy/tropical spastic paraparesis (HAM/TSP), and infectious dermatitis. The virus is transmitted by transfusion of unscreened blood, by breast feeding of infants and young children, and by sexual intercourse among adults. A priority of the VEB is to improve the understanding of the process by which HTLV-I causes ATL and other serious diseases which could lead to interventions to prevent and possibly even treat affected people. Shunro Sonoda, MD, DMedSci, is the Ex-Professor and Chairman of the Department of Virology and Island Medicine and is Professor Emeritus of the Research Development Center of Kagoshima University, Kagoshima, Japan. Prof. Sonoda has published 108 papers in the scientific peer review literature, plus 16 book chapters and monographs. For more than 20 years, his career has been highly focused on the human and viral molecular genetics of HTLV-I infection and the diseases related to HTLV-I infection. Dr. Sonoda will be providing the following services to the VEB: 1) review the scientific protocols and field manuals for all HTLV-I projects currently being conducted by the VEB, and write a critique of each project highlighting the strengths and weaknesses of each project; 2) protocol development, field implementation, interim evaluation, and final evaluation of a clinical trial to examine the effect of daily consumption of capsules containing green tea extract on HTLV-I proviral load and on signs and symptoms of TSP among HTLV-I-infected adults in Jamaica; 3) select from the biospecimen repository specimens to be tested for HTLV-I proviral load, HTLV-I antibodies and antibody titers, human leukocyte antigen (HLA) and other human gene testing, and other related assays; 4) data analyses, particularly but not exclusively HLA genotype and haplotype data in both population and family studies; 5) summarize the results of analyses and in writing reports for internal use and for submission to the peer review scientific literature for publication. Dr. Sonoda?s deep and broad specific experience with HTLV-I research make him uniquely qualified to provide these services. He is unquestionably one of the leading authorities on laboratory procedures for determining and for interpreting human leukocyte antigen (HLA) genotype and haplotype. He discovered the anti-proliferative and anti-viral effects of green tea polyphenols and conducted the first clinical trial of green tea extract against HTLV-I, demonstrating beneficial effect of reducing the level of HTLV-I in the blood cells. Dr. Sonoda is the only known source to the NCI researchers with this knowledge and expertise who can meet their needs. This is not a solicitation for competitive quotations. However, if any interested party believes it can meet the entire above requirement, they may submit a statement of capabilities. All information furnished shall be in writing and must contain sufficient detail to allow the NCI researcher to determine if it can meet the requirements of this synopsis. An original and one copy of the capability statements must be received in the Contracting Office by 1PM EST (local Washington, D.C. time) on March 31, 2005. Faxed and emailed capability statements are NOT authorized. All questions must be in writing and may be emailed to Debbie Moore at dm170b@nih.gov or faxed (301) 402-4513. It is the vendor?s responsibility to call (301) 402-4509 and verify that questions were received. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. NAICS: 541990; Size Standard is 6 million.
- Record
- SN00769817-W 20050318/050316211756 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |